ストックスクリーナーアプリを入手
188.75
3.13%
5.72
プレマーケット:
187.50
-1.25
-0.66%
前日終値:
$183.03
開ける：
$182.61
24時間の取引高:
2.28M
Relative Volume:
0.79
時価総額：
$40.13B
収益：
$742.00K
当期純損益:
$-1.37B
株価収益率:
-26.69
EPS:
-7.0731
ネットキャッシュフロー:
$-1.07B
1週間 パフォーマンス:
+5.34%
1か月 パフォーマンス:
+11.35%
6か月 パフォーマンス:
+60.46%
1年 パフォーマンス:
+402.93%
1日の値動き範囲:
$180.00
$193.53
1週間の範囲:
$176.00
$193.53
52週間の値動き範囲:
$34.00
$193.82
Revolution Medicines Inc Stock (RVMD) Company Profile
名前
Revolution Medicines Inc
セクター
電話
650-481-6801
住所
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD vs VRTX, REGN, ARGX, ALNY
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
188.75 | 38.91B | 742.00K | -1.37B | -1.07B | -7.0731 |
VRTX
Vertex Pharmaceuticals Inc
|
473.09 | 119.94B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
651.91 | 68.27B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
924.60 | 53.28B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
268.74 | 35.65B | 4.29B | 577.22M | 641.34M | 4.2086 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-16 | 再開されました | Jefferies | Buy |
| 2026-02-27 | 再開されました | UBS | Buy |
| 2025-11-18 | 開始されました | Wolfe Research | Outperform |
| 2025-11-03 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-10-21 | 開始されました | Mizuho | Outperform |
| 2025-10-16 | 再開されました | Stifel | Buy |
| 2025-09-12 | 再開されました | Raymond James | Strong Buy |
| 2025-09-05 | 開始されました | Truist | Buy |
| 2025-08-19 | 開始されました | Piper Sandler | Overweight |
| 2025-08-15 | 開始されました | Wells Fargo | Overweight |
| 2025-07-15 | 開始されました | Goldman | Buy |
| 2024-07-16 | 繰り返されました | Needham | Buy |
| 2024-07-12 | 開始されました | Barclays | Overweight |
| 2024-07-08 | 開始されました | Jefferies | Buy |
| 2024-04-12 | 繰り返されました | Needham | Buy |
| 2024-04-10 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | 開始されました | Piper Sandler | Overweight |
| 2024-01-05 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-01-04 | 開始されました | Wedbush | Outperform |
| 2023-11-16 | 開始されました | Raymond James | Outperform |
| 2023-02-28 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-12-14 | 開始されました | Needham | Buy |
| 2022-10-21 | 開始されました | Oppenheimer | Outperform |
| 2022-05-20 | 開始されました | BofA Securities | Neutral |
| 2022-03-01 | アップグレード | Stifel | Hold → Buy |
| 2021-09-23 | 開始されました | Stifel | Hold |
| 2021-08-12 | ダウングレード | Goldman | Buy → Neutral |
| 2021-05-18 | 開始されました | Goldman | Buy |
| 2020-05-21 | 開始されました | H.C. Wainwright | Buy |
| 2020-03-09 | 開始されました | Cowen | Outperform |
| 2020-03-09 | 開始されました | Guggenheim | Buy |
| 2020-03-09 | 開始されました | JP Morgan | Neutral |
すべてを表示
Revolution Medicines Inc (RVMD) 最新ニュース
Revolution Medicines (RVMD) Is Up 5.3% After FDA Priority Review For Pancreatic Cancer Drug Approval Bid - simplywall.st
Bragar Eagel & Squire, P.C. Reminds Erasca, Inc. (ERAS) Investors that a Class Action Lawsuit Has Been Filed Against Erasca and Encourages Investors to Contact the Firm Before August 10th - GlobeNewswire Inc.
FDA Accepts RVMD's Filing for Daraxonrasib in Pancreatic Cancer - Zacks Investment Research
RVMD Maintains Rating by Wedbush -- Price Target Raised to $192.10 - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
Revolution Medicines' Application for Pancreatic Cancer Treatment Accepted by FDA - Moomoo
Revolution Medicines' New Drug Application For Daraxonrasib Accepted For Review By U.S. FDA - TradingView
Revolution Medicines (RVMD) Sees FDA Acceptance for Daraxonrasib Review - GuruFocus
FDA accepts review of Revolution Medicines' dar... - Pluang
Oral Investigational Medicine for Pancreatic Cancer Is Accepted for FDA Review - Stock Titan
Revolution Medicines, Inc. (RVMD) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
(RVMD) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
‘Pharma Bro’ Martin Shkreli Defends Revolution Medicines’ Pancreatic Cancer Study Data: ‘Progress Compounds’ - Stocktwits
RVMD Maintained by Needham -- Price Target Raised to $236 - GuruFocus
Revolution Medicines, Inc. (RVMD) Stock Analysis: Why Analysts Are Bullish on This $39.58 Billion Biotech Innovator - DirectorsTalk Interviews
Why is Revolution Medicines (RVMD) up 9.3% since last earnings report? - MSN
Erasca: A Credible Rival To Revolution's Daroxonrasib, At A Cheaper Price Point (ERAS) - Seeking Alpha
Revolution Medicines Gains as Investors Continue to Digest Clinical and Regulatory Momentum - Quiver Quantitative
All eyes on data on Biogen’s tau therapy - STAT
Revolution Medicines, Inc. (RVMD) Stock Analysis: A Biotech Titan with a Promising 7.17% Upside - DirectorsTalk Interviews
Truist reiterates Buy on Revolution stock, keeps $210 target By Investing.com - Investing.com India
Truist Financial Maintains Revolution Medicines(RVMD.US) With Buy Rating - Moomoo
Revolution Medicines Price Target Raised to $235.00/Share From $205.00 by Guggenheim - Moomoo
RVMD Maintained by Guggenheim -- Price Target Raised to $235 - GuruFocus
Revolution Medicines Is Maintained at Buy by Guggenheim - Moomoo
Better Growth Buy: Axsome vs Revolution Medicines - The Motley Fool
Revolution Medicines (RVMD) Wins Faster Reviews, Is The Valuation Already Too Rich? - simplywall.st
EMA’s Review of Daraxonrasib in PDAC Accelerated Under Phased Review Process - CancerNetwork
Drug that could extend lives of Canadians with pancreatic cancer remains out of reach for patients - The Globe and Mail
Revolution Medicines (RVMD) Holds Steady Near Resistance—Consolidation or Catalyst Ahead?Vol Target Rebalance - dars.gov.et
EMA speeds up review of Revolution Medicines' d... - Pluang
Revolution Medicines Says EMA Begins Phased Review of Daraxonrasib for Pancreatic Cancer as FDA NDA Submission Nears Completion - Quiver Quantitative
European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process - The Manila Times
Revolution Medicines, Inc. - Via Ritzau
EMA fast-tracks Revolution Medicines' pancreatic cancer drug review - Stock Titan
Revolution Medicines wins EU fast track review for cancer drug - Seeking Alpha
EMA fast-tracks review of Revolutions' experimental pancreatic cancer pill - Reuters
Pulling the plug on cancer: Agios Pharmaceuticals, Revolution Medicines, and Vidac Pharma - Stockhouse
There's a Revolution in Cancer. But Can Big Pharma Afford It? -- Heard on the Street -- WSJ - Moomoo
Revolution Medicines stock hits all-time high at 193.12 USD By Investing.com - Investing.com South Africa
RVMD Reiterates by HC Wainwright & Co. -- Price Target Maintained at $195 - GuruFocus
Revolution Medicines stock hits all-time high at 193.12 USD - Investing.com
RVMD Maintained by Mizuho -- Price Target Raised to $215 - GuruFocus
H.C. Wainwright Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $195 - Moomoo
Mizuho Raises Price Target on Revolution Medicines to $215 From $185, Keeps Outperform Rating - Moomoo
Will Strong Early Zoldonrasib Pancreatic Data Change Revolution Medicines' (RVMD) RAS-Focused Narrative? - simplywall.st
Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy? - AOL.com
Revolution Medicines Inc (RVMD) 財務データ
収益
当期純利益
現金流量
EPS
Revolution Medicines Inc (RVMD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Patel Sushil | Director |
Jun 29 '26 |
Sale |
187.99 |
5,580 |
1,048,967 |
21,656 |
0.66%
大文字化:
|
ボリューム (24 時間):